Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl
Fig 2
Priorities for adding cardiovascular risk reduction therapies guided by LDL-C above or below 100 mg/dl on maximal statin and lifestyle therapy in patients with ASCVD.
When LDL-C levels are above 100 mg/dl, log linear association evidence for higher ASCVD risk groups and ASCVD risk reductions are substantial. When LDL-C is less than 100 mg, those patient groups with an extensive burden of atherosclerosis and multiple comorbidities, including familial hypercholesterolemia, are likely to have the greatest risk reduction from LDL-C lowering therapy.